title: Part XIII. Systemic antifungal therapy.
abstract: Until the last decade of the 20th century, intravenous amphotericin B deoxycholate was the only agent available to treat the relatively rare occurrence of serious systemic fungal infections. In response to an explosion in the incidence of systemic fungal infections, within a 15 year period, four new classes of antifungal agents were introduced: the triazoles, liposomal amphotericin B preparations, an allylamine, and echinocandins (Table 1). So an updated review of antifungal therapy is in order.
authors.affiliation: Infectious Diseases Secton, Oklahoma City, OK 73190, USA.
authors.forename: Kristin H
authors.initials: KH
authors.lastname: Busse
authors.forename: Chris A
authors.initials: CA
authors.lastname: Gentry
authors.forename: Michael S
authors.initials: MS
authors.lastname: Bronze
authors.forename: Ronald A
authors.initials: RA
authors.lastname: Greenfield
mesh_terms: D000935:Antifungal Agents / Q000145:classification* / Q000627:therapeutic use*; D020314:Central Nervous System Fungal Infections / Q000188:drug therapy*; D006801:Humans; D008172:Lung Diseases, Fungal / Q000188:drug therapy*
chemical_list: D000935:Antifungal Agents